Survey of 300 Rheums, GI, Derms - concerns w/ new biosimilars - majority say economics arent favorable to switch to biosimilar - Yet majority "very to somewhat” comfortable w/ biosimilars - US: Slow biosimilar uptake due to disappointing costs https://t.co/6dUR4gA3I5 https://t.co/2bLzE70h6y